Interestingly, Bruton’s tyrosine kinase (BTK) inhibitors have shown selective activity in MYD88L265P mutated DLBCL of the non-GC type, and numerous combination regimens currently are being tested in clinical trials [21]. Here, BTK is linked to diffuse large B-cell lymphoma.